SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
NuVasive, Inc. (NUVA) trades at a trailing P/E of 52.3. Trailing earnings yield is 1.91%.
Criteria proven by this page:
- VALUE (57/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Trailing Earnings Yield 1.91% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
- Analyst consensus target $58.00 (+45.9% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 48/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
57/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NUVA
Valuation Multiples
P/E (TTM)52.3
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1.90
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.76
Book Value / Share$0.00
Revenue / Share$20.95
FCF / Share$0.00
Yields & Fair Value
Earnings Yield1.91%
Dividend Yield0.00%
Analyst Target$58.00 (+45.9%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$0.17 |
$685.17M |
$7.9M |
1.2% |
| 2014 |
$-0.36 |
$762.42M |
$-16.72M |
-2.2% |
| 2015 |
$1.26 |
$811.11M |
$66.29M |
8.2% |
| 2016 |
$0.69 |
$962.07M |
$37.15M |
3.9% |
| 2017 |
$1.50 |
$1.03B |
$83.01M |
8.1% |
| 2018 |
$0.24 |
$1.1B |
$12.48M |
1.1% |
| 2019 |
$1.23 |
$1.17B |
$65.23M |
5.6% |
| 2020 |
$-0.72 |
$1.05B |
$-37.15M |
-3.5% |
| 2021 |
$-1.24 |
$1.14B |
$-64.09M |
-5.6% |
| 2022 |
$0.76 |
$1.2B |
$40.41M |
3.4% |
